You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The New York Times reports the Infectious Disease Research Institute in Seattle has laid off about a third of its researchers.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
In PNAS this week: analysis of extensively drug-resistant Mycobacterium tuberculosis strain, regulation of obesity-linked gene, and more.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
In PLOS this week: genes and pathways linked to multiple sclerosis, Salmonella enterica diversity in reptiles, and more.
Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.
Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.
According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.
In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.